Genentech, the US subsidiary of Roche, announced final survival results from the Phase III «Cleopatra» study, which showed that adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer by 15.7 months.
According to Dr. Sandra Swain, an oncologist and professor at Georgetown University, this survival improvement is "unprecedented among studies of metastatic breast cancer”. The data also showed that the risk of death was reduced by 32 percent for people who received the Perjeta regimen, compared to those who received Herceptin and chemotherapy.
The complete of Genentech
News article by FiercePharma